Abstract Title:

Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients.

Abstract Source:

Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36. PMID: 17944002

Abstract Author(s):

Gary D Friedman, E Dawn Flick, Natalia Udaltsova, James Chan, Charles P Quesenberry, Laurel A Habel

Article Affiliation:

Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA. [email protected]

Abstract:

PURPOSE: Determine the risk of cancer in statin users. METHODS: Risk of cancer in up to 9.4 years after first recorded receipt of statins was evaluated in subscribers of an integrated health care program in northern California. Statin use and cancer development were ascertained from the program's pharmacy records and cancer registry from August 1994 to December 2003. RESULTS: Most of the 361,859 statin users received lovastatin, simvastatin or both. Results are presented from analyses with 2-year lag and use for over 5 years. Most of the observed associations were likely due to chance or confounding. The few associations that seemed less readily explainable were increased risk of cancers of the thyroid, esophagus and urinary tract and decreased risk of colon cancer in men. Increased risk of lung cancer was the only nominally statistically significant positive association in women and could be partially attributable to their smoking habits. CONCLUSIONS: Overall this study provided no strong evidence of either causation or prevention of cancer by statins.

Study Type : Human Study
Additional Links

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.